RESEARCH

Open Access

Robustness of sepsis-3 criteria in critically ill patients



Diana M. Verboom^{1,2*}, Jos F. Frencken^{1,2}, David S. Y. Ong^{1,3}, Janneke Horn⁴, Tom van der Poll^{5,6}, Marc J. M. Bonten^{1,7}, Olaf L. Cremer² and Peter M. C. Klein Klouwenberg⁸

Abstract

Background: Early recognition of sepsis is challenging, and diagnostic criteria have changed repeatedly. We assessed the robustness of sepsis-3 criteria in intensive care unit (ICU) patients.

Methods: We studied the apparent incidence and associated mortality of sepsis-3 among patients who were prospectively enrolled in the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) cohort in the Netherlands, and explored the effects of minor variations in the precise definition and timing of diagnostic criteria for organ failure.

Results: Among 1081 patients with suspected infection upon ICU admission, 648 (60%) were considered to have sepsis according to prospective adjudication in the MARS study, whereas 976 (90%) met sepsis-3 criteria, yielding only 64% agreement at the individual patient level. Among 501 subjects developing ICU-acquired infection, these rates were 270 (54%) and 260 (52%), respectively (yielding 58% agreement). Hospital mortality was 234 (36%) vs 277 (28%) for those meeting MARS-sepsis or sepsis-3 criteria upon presentation (p < 0.001), and 121 (45%) vs 103 (40%) for those having sepsis onset in the ICU (p < 0.001). Minor variations in timing and interpretation of organ failure criteria had a considerable effect on the apparent prevalence of sepsis-3, which ranged from 68 to 96% among those with infection at admission, and from 22 to 99% among ICU-acquired cases.


Conclusion: The sepsis-3 definition lacks robustness as well as discriminatory ability, since nearly all patients presenting to ICU with suspected infection fulfill its criteria. These should therefore be specified in greater detail, and applied more consistently, during future sepsis studies.

Trial registration: The MARS study is registered at ClinicalTrials.gov (identifier NCT 01905033).

Keywords: Sepsis, Septic shock, Incidence, Mortality, Critical care, Infection

Introduction

Sepsis is a life-threatening disease caused by a dysregulated host response to infection. Unfortunately, both early recognition and definitive confirmation of the diagnosis have proven to be difficult as sepsis is a very heterogeneous syndrome [1]. Since 1991, conceptual thinking about sepsis has focused on the presence of a systemic inflammatory response syndrome (SIRS). However, SIRS criteria are neither sensitive nor specific for infection and do not necessarily indicate a dysregulated or life-threatening host response [2, 3].



Sepsis-3 definitions were developed to improve risk stratification among patients with a suspected infection, and their predictive validity regarding unfavorable clinical outcomes have been confirmed several times by now [4-12]. Rather than a systemic inflammatory response syndrome, these sepsis definitions require the development of organ failure during an infectious episode, which is operationalized by an increase in the Sequential Organ Failure Assessment (SOFA) score [13, 14]. Similarly, the septic shock-3 definition requires the presence of elevated serum lactate levels in addition to fluid-resistant hypotension [15].



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: d.m.verboom-2@umcutrecht.nl

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands

²Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands

Full list of author information is available at the end of the article

Sepsis-3 definitions were also established to increase uniformity among reported incidence and mortality rates [13–15]. A consistent diagnosis of sepsis and septic shock between centers is particularly important for research and benchmarking purposes. Clinical data can be sensitive to different coding approaches, complicating comparisons of sepsis epidemiology among different cohorts [16, 17]. However, as only a little attention has been focused on the robustness of sepsis-3 criteria, we studied the effects of minor variations in the interpretation of the criteria on the incidence and related mortality of sepsis-3.

Materials and methods

Study design and population

This study was embedded within the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) cohort [18]. Consecutive adult patients with newly suspected infection either upon presentation or during ICU stay were enrolled in two Dutch tertiary ICUs between June 2011 and April 2015 (University Medical Center Utrecht) or between June 2011 and January 2014 (Academic Medical Center Amsterdam).

Patients who had been admitted to another ICU for more than 1 day before transfer to one of the study centers were excluded, because information about possible previous infections and organ failures was not available. Patients who had been treated for an infection in the week prior to ICU admission and subsequently were admitted with a new infection were also excluded to avoid possible overlap between pre-existent and newly acquired organ failures. The institutional review board approved an opt-out consent procedure (protocol number 10-056C).

Data and definitions

Trained researchers attended daily multidisciplinary rounds in the participating ICUs and prospectively recorded the presence of infection, SIRS, and organ failure [18, 19]. In this study, we use the terms "MARS-sepsis" and "MARS-shock" to indicate severe sepsis and septic shock according to prospective assessment of the presence of SIRS and organ failure, based on the 1991 and 2001 definitions of sepsis [20, 21] (see Table 1). The incidence and related mortality of MARS-sepsis are shown for illustrative purposes only and are not intended to provide a head to head comparison with sepsis-3 (which would have no clinical significance) nor to appraise the robustness of sepsis-3.

The terms "sepsis-3" and "septic shock-3" were used to indicate events meeting the updated definitions. Organ failure for sepsis-3 was defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [14]. We operationalized organ failure as an

Table 1 Sepsis definition	۱S
-----------------------------------	----

Old sepsis					
MARS-sepsis	Presence of \geq 2 SIRS criteria and organ failure within a 4-day window around suspected infection ^{a, b}				
MARS-septic shock	MARS-sepsis and use of vasopressor for hypotension within a 4-day window ^{a, c}				
Sepsis-3					
Sepsis-3 (4-day window)	Suspected infection and an acute SOFA score increase of \geq 2 points within a 4-day window ^a				
Septic shock-3	Sepsis-3 and vasopressor-dependent hypotension (i.e., circulatory SOFA score \geq 2) plus an increased serum lactate level of > 2 mmol/L within a 4-day window ^{a, d}				
Assessments of mino	r variations in diagnostic criteria				
Reduced observation window	Similar to sepsis-3, but with a 2-day window around suspected infection (i.e., an increase between the day before and the day of the onse of infection)				
Absolute SOFA score	Suspected infection and an absolute SOFA score of \geq 2 points at the day of onset of infection and within a 4-day window ^a				
Septic shock-3 ignoring lactate	Similar to septic shock-3, but without the requirement of increased serum lactate levels if not measured				

SIRS = Systemic Inflammatory Response Syndrome, *SOFA* = Sequential Organ Failure Assessment


^a 4-day window = an observation window ranging from 2 days before the initiation of empirical antibiotics (onset of infection) until 1 day after the onset of infection

^b Organ failure for MARS-sepsis was defined as the following signs of organ hypoperfusion or dysfunction: areas of mottled skin; capillary refilling requiring 3 s or longer; urine output < 0.5 ml/kg for at least 6 h, > 1.5-fold elevated creatinine or renal replacement therapy; lactate > 2 mmol/l; abrupt change in mental status; abnormal electroencephalographic findings consistent with septic encephalopathy; platelet count < 100,000 platelets/ml or disseminated intravascular coagulation; acute respiratory distress syndrome and cardiac dysfunction, as defined by echocardiography or direct measurement of the cardiac index [22]"

^cMARS-septic shock was defined as the use of norepinephrine in a dose of > 100 ng/kg/min for more than 50% of an observation day, dopamine > 5 mcg/kg/min or epinephrine for hypotension despite adequate fluid resuscitation (e.g., not including induced hypertension)

^dLactate was considered increased if it was increased once at any day during the 4-day time window

acute SOFA score increase of ≥ 2 points compared to preexisting (acute or chronic) organ dysfunction before the onset of infection (Table 1). The increase in SOFA score had to occur between 2 days before the onset of infection and 1 day after the onset of infection (i.e., a 4-day window, see Fig. 1). This window was used because organ dysfunction may occur prior to, near the moment, or after the infection is recognized [5]. An infection was registered when empirical antimicrobial therapy was started by attending clinicians irrespective of the presence of SIRS or organ failure, and this day was regarded as its onset. Subsequently, the likelihood of each infection was subsequently adjudicated as none, possible, probable or definite, using detailed definitions derived from Center of Disease Control and International Sepsis Forum Consensus



 \geq 2 points within the 4-day (or 2-day) time-window. However, case 1 fulfills the criteria if sepsis-3 definition as there is no SOFA score increase of score of \geq 2 (both in the 4-day and 2-day time-window). Case 2 fulfills the sepsis-3 criteria since there is an increase of \geq 2 points between day 0 and day 1. In a reduced time-window, there is no increase observed between the day before infection and day of the onset of infection, and sepsis-3 criteria are not met

Conference criteria [18, 23, 24]. Only first ICU infections occurring during a hospital admission were included for analysis. Infections present at admission (having onset between 1 day before and 2 days after ICU admittance) and ICU-acquired infections (having onset more than 2 days after ICU admittance) were analyzed separately since we hypothesized that the extent of new organ failure might vary between these types of infection.

To reconstruct baseline SOFA scores, raw pre-ICU clinical data were extracted from the hospital electronic health care record. All ICU data were collected prospect-ively [19]. In cases on dialysis dependency or having chronic renal insufficiency, the renal SOFA was assumed to be 3.


To evaluate the robustness, we assessed the influence of minor variations in the implementation of the sepsis-3 definitions (see Table 1). We based our variations on the methodology that was used in previous studies [4, 6, 13, 15]. First, we shortened the time window of observation by only including the day of clinical diagnosis and 1 day before (2-day window). Second, we explored the effects of an absolute SOFA score at the time of recognition of infection. Third, to mimic settings in which lactate is not always available, only vasopressordependent hypotension was required to fulfill the septic shock definition in cases where lactate levels were missing (see Table 1 and Fig. 1 for further explanations).

Statistical analyses

We calculated apparent incidences and related inhospital mortality of sepsis-3 and MARS-sepsis. We calculated the percent agreement as the percentage of cases in which two sepsis definitions corresponded with each other. Sensitivity analysis was performed by excluding subjects with rejected infection (i.e., a post hoc likelihood of none). All analyses were performed and reported separately for infections at admission and ICU-acquired infections. Missing data were handled as described in Additional file 1: Table S1. Differences at baseline and clinical characteristics between the subgroups were analyzed using a Mann-Whitney U test, chisquare test, or McNemar test, as appropriate. Differences in mortality were calculated accounting for partially overlapping samples [25]. A p value < 0.05was considered statistically significant. All analyses were performed using SAS 9.2 (SAS Institute Inc.).

Results

Among 1743 patients treated for an infection in the ICU, 1081 with an infection at ICU admission and 501 with an ICU-acquired infection remained for analysis (Figs. 2 and 3). Patient and infection characteristics are presented in Table 2.




Incidence and associated mortality

Table 3 shows the apparent incidences and related percent agreement of sepsis and septic shock according to the various definitions.

Compared to prospectively recorded MARS-sepsis events, more patients fulfilled sepsis-3 and septic shock-3

criteria at ICU admission (60% vs 90%, and 27% vs 38%, respectively). Furthermore, agreement between the definitions was only 64% and 80%, respectively. For patients with ICU-acquired infections, the overall incidences of sepsis (54% vs 52%) and septic shock (19% vs 18%) were similar, yet the MARS and sepsis-3 criteria selected different



	Infection at admission ($N = 1081$)			ICU-acquired infection ($N = 501$)			
	No sepsis-3 $(N = 105)$	Sepsis-3 (N = 976)	p value	No sepsis-3 $(N = 241)$	Sepsis-3 (N = 260)	<i>p</i> valu	
Age (years)	61 (42, 69)	64 (53, 73)	0.005	62 (51, 71)	61 (50, 71)	0.64	
Male	64 (61%)	621 (64%)	0.59	175 (73%)	177 (68%)	0.27	
Charlson comorbidity index	0 (0, 2)	1 (0, 2)	0.002	0 (0, 2)	0 (0, 2)	0.33	
Chronic renal insufficiency ^a	9 (9%)	114 (12%)	0.34	20 (8%)	25 (10%)	0.6	
APACHE IV Score	69 (50, 89)	83 (66, 03)	0.001	76 (58, 95)	76 (62, 99)	0.24	
Medical admission	69 (66%)	726 (74%)	0.06	102 (42%)	104 (40%)	0.60	
At onset of infection							
Days from ICU admission	0 (0, 2)	0 (0, 0)	< 0.001	6 (4, 8)	6 (4, 9)	0.32	
Hospital-acquired infection	65 (62%)	449 (46%)	0.002	100%	(100%)	-	
Vasopressor use	36 (35%)	663 (68%)	< 0.001	98 (41%)	141 (54%)	0.002	
Mechanical ventilation	78 (74%)	664 (68%)	0.19	189 (78%)	240 (92%)	< 0.00	
Lactate measured	37 (35%)	676 (69%)	< 0.001	72 (30%)	109 (42%)	0.005	
Lactate	1.8 (1, 4)	3 (2, 5)	0.002	2 (1, 2)	2 (2, 4)	< 0.00	
≥ 2 SIRS criteria	88(83%)	900 (92%)	0.004	205 (85%)	226 (87%)	0.55	
SOFA score	2 (1, 4)	6 (4, 9)	< 0.001	6 (4, 8)	8 (5, 10)	< 0.00	
Source of infection			0.08			0.39	
Pulmonary tract	70 (67%)	533 (55%)		138 (57%)	154 (59%)		
Abdominal tract	7 (7%)	156 (16%)		7 (3%)	12 (5%)		
Urinary tract	6 (6%)	57 (6%)		1 (0%)	1 (0%)		
CRBSI	1 (1%)	15 (2%)		36 (15%)	25 (10%)		
Other	21 (20%)	215 (22%)		59 (24%)	68 (26%)		
Infection likelihood			0.02			0.13	
 None 	11 (10%)	99 (10%)		85 (35%)	82 (32%)		
 Possible 	46 (44%)	298 (31%)		109 (45%)	105 (40%)		
 Probable 	30 (29%)	293 (30%)		31 (13%)	43 (17%)		
 Definite 	18 (17%)	286 (29%)		16 (7%)	30 (12%)		
Outcome							
Length of ICU stay (days)	2 (1, 6)	4.0 (2, 10)	< .001	6 (3, 13)	7 (3, 15)	0.12	
Length of hospital (days)	13 (5, 29)	15 (7, 31)	0.09	19 (9, 34)	22 (9, 38)	0.64	
ICU mortality	8 (8%)	197 (20%)	0.002	52 (22%)	82 (32%)	0.01	
Hospital mortality	12 (11%)	277 (28%)	0.001	72 (30%)	103 (40%)	0.05	
90-day mortality	20 (19%)	328 (34%)	0.002	83 (35%)	114 (44%)	0.03	

 Table 2 Characteristics of patients with infection on admission and with ICU-acquired infection and stratified by presence of sepsis-3 criteria

APACHE = acute physiologic and chronic health evaluation, SIRS = systemic inflammatory response syndrome, ICU = intensive care unit, CRBSI = catheter-related bloodstream infection. Continuous data are presented as medians (IQR), dichotomous data are presented as frequencies (%) ^aCreatinine >170 mmol/L or dialysis dependency

individuals (58% and 81% agreement for sepsis and septic shock, respectively) (Table 3).

Hospital mortality was lower for patients with sepsis-3 and septic shock-3 than for patients with MARS-sepsis and MARS-shock (Table 3). Indeed, those patients who were exclusively identified by sepsis-3 at admission (33% of all patients) had a lower mortality rate than patients with organ failure according to both MARS-sepsis and sepsis-3 (37% vs 14%, respectively) (Additional file 1: Table S2). Nevertheless, mortality was > 10% for all definitions (Table 3, Additional file 1: Table S2 and Table S3). There were 110 (10%) and 167 (33%) patients with a rejected infection (i.e., those with a post hoc likelihood rated as none) at ICU admittance and during admission respectively. The exclusion of patients with rejected infection had a negligible effect on apparent sepsis incidences, mortality, and agreement (Table 3).

Robustness of the sepsis-3 definitions

Table 4 shows the results of the analyses to assess the robustness of sepsis-3 criteria. Minor variations in the

|--|

	Ν	Sepsis-3 incidence, % (95%CI)	MARS-sepsis incidence, % (95%CI)	Agreement (%)	p value	Sepsis-3 mortality, % (95%Cl) ^b	MARS-sepsis mortality, % (95%CI) ^b	p value
Complete cohort	1582							
 Infection at admission 	1081	90 (88–92)	60 (57–63)	64	< 0.001	28 (26–31)	36. (33–40)	< 0.001
 ICU-acquired infection 	501	52 (48–56)	54 (50–58)	58	0.49	40 (34–46)	45 (39–51)	< 0.001
Probable infection cohort ^c	1304							
 Infection at admission ^c 	971	90 (88–92)	61 (58–64)	65	< 0.001	29 (26–32)	37 (33–41)	< 0.001
 ICU-acquired infection ^c 	334	53 (48–59)	56 (51–62)	59	0.39	44 (37–51)	51 (42–56)	< 0.001
		Septic shock-3 incidence, % (95%CI) ^a	MARS-shock incidence, % (95%CI) ^a	Agreement (%)	p value	Septic shock-3 mortality, % (95%CI) ^b	MARS-shock mortality, % (95%CI) ^b	
	Ν							
Complete cohort	1582							
 Infection at admission 	1081	38 (35–41)	27 (24–30)	80	< 0.001	41 (36–46)	50 (45–56)	< 0.001
 ICU-acquired infection 	501	18 (15–21)	19 (16–23)	81	0.47	57 (47–67)	69 (59–78)	< 0.001
Probable infection cohort ^c	1304							
 Infection at admission ^c 	971	39(36–42)	28 (25–31)	79	< 0.001	42 (37–47)	51 (46–57)	< 0.001
 ICU-acquired infection ^c 	334	19 (15–23)	22 (18–27)	83	0.11	63 (50–74)	73 (62–82)	< 0.001

ICU=intensive care unit

^a McNemar test comparing the incidence of sepsis-3 and MARS definitions

^b Mortality reflects in-hospital mortality. For all definitions, mortality of the sepsis-3 criteria was significantly lower than mortality of the MARS definitions (*p* < 0.001) ^cA subgroup of patients in whom the infection diagnosis was either possible, probable or definite based on microbiology, clinical symptoms, and radiology, as defined by post hoc assessment

timing of observations and criteria for organ failure considerably affected the apparent incidence of sepsis-3 at admission, ranging from 68 to 96% for the most restrictive and the most liberal definition, respectively. Using the same criteria, the incidence of septic shock-3 varied from 30 to 42%. For ICU-acquired infections, the incidence of sepsis-3 and septic shock-3 ranged from 22 to 99% and from 7 to 28%, respectively. Whereas these minor variations did not affect hospital mortality rates for infections at admission, and only marginally for ICUacquired sepsis (Table 4).

Discussion

We assessed the incidence, mortality, and robustness of the sepsis-3 definitions in a large prospectively monitored cohort of ICU patients. We found that virtually all patients with a suspected infection met clinical criteria for organ failure and, as such, the sepsis-3 criteria did not have discriminative power in our setting. Furthermore, minor variations in the precise interpretation of the criteria required to meet the sepsis-3 definitions considerably impacted the apparent incidences of both sepsis and septic shock, while mortality remained comparable among the variations.

An anticipated advantage of the sepsis-3 definitions is that they may increase the comparability of sepsis incidence and related mortality among studies. Organ failure is explicitly defined by means of the SOFA score, possibly reducing subjective interpretation. Still, studies published to date have used many subtle variations on the original definition. For example, the original publication suggested to define organ failure as an acute change in the SOFA score of ≥ 2 points as a consequence of infection [14]. Subsequent validation studies, however, have largely disregarded this requirement of an acute SOFA increase. Instead, they used an absolute SOFA score of ≥ 2 points, applied different time-windows, and used different ways of taking chronic comorbidities into account [4-10, 13]. By applying similar (minor) variations to our data, we

Table 4 The influence of minor variations in diagnostic criteria on the apparent incidence and related mortality of sepsis

Core definitions and minor variations	Incidence, % (95%Cl)	Agreement (%) ^a	p value $^{\rm b}$	Mortality, % (95%Cl)	p value
Infection at admission					
Sepsis-3					
Core definition: SOFA increase (4-day window)	90 (88–92)	n/a	n/a	28 (26–31)	n/a
 SOFA increase (2-day window) 	68 (66–71)	78	< 0.001	28 (25–31)	0.50
 Absolute SOFA ≥ 2 (4-day window) 	96 (95–97)	94	< 0.001	27 (25–30)	0.45
 Absolute SOFA ≥ 2 at onset of infection 	89 (87–91)	88	0.30	28 (25–31)	0.64
Septic shock-3					
Core definition: SOFA increase (4-day window)	38 (35–41)	n/a	n/a	41 (36–46)	-
 SOFA increase (2-day window) 	30 (27–32)	92	< 0.001	41 (36–46)	0.98
 Absolute SOFA ≥ 2 (4-day window) 	39 (36–42)	99	< 0.001	41 (36–45)	0.81
 Absolute SOFA ≥ 2 at onset of infection 	37 (34–40)	97	0.25	41 (37–46)	0.83
 Shock-3 ignoring lactate 	42 (40–45)	95	< 0.001	41 (36–45)	0.93
ICU-acquired infection					
Sepsis-3					
Core definition: SOFA increase (4-day window)	52 (48–56)	n/a	n/a	40 (34–46)	n/a
 SOFA increase (2-day window) 	22 (19–26)	70	< 0.001	42 (33–51)	0.31
 Absolute SOFA ≥ 2 (4-day window) 	99 (97–100)	53	< 0.001	35 (31–39)	<0.01
 Absolute SOFA ≥ 2 at onset of infection 	96 (94–98)	53	< 0.001	35 (31–40)	<0.01
Septic-shock-3					
Core definition: SOFA increase (4-day window)	18 (15–21)	n/a	n/a	57 (47–67)	n/a
 SOFA increase (2-day window) 	7 (5–9)	89	< 0.001	65 (48–79)	0.05
 Absolute SOFA ≥ 2 (4-day window) 	27 (23–31)	91	< 0.001	54 (45–62)	0.26
 Absolute SOFA ≥ 2 at onset of infection 	26 (22–30)	90	< 0.001	53 (44–61)	0.14
 Shock-3 ignoring lactate 	28 (24–32)	90	< 0.001	50 (42–58)	0.01

SOFA = Sequential Organ Failure Assessment. Incidences are the apparent incidences of the various sepsis-3 variations

^aPercentage agreement indicates the agreement of the incidence with the incidence of the core definition (≥ 2 increase in SOFA score) of sepsis-3 ^bMcNemar test comparing the incidence of the core definition and minor definitions

menental test comparing the incluence of the core definition and minor definitions

explored the robustness of the criteria and observed considerable variations in the apparent incidences of sepsis-3. Similar variations in the incidence of sepsis-3 and septic shock-3 are likely to occur in other studies, hence affecting the comparability of study results. Standardization of the operationalization of sepsis-3 criteria is therefore paramount to improve the generalizability of studies.

One of the most used and straightforward methods of defining organ failure for sepsis diagnosis is the use of an absolute SOFA score, thereby disregarding any pre-existent organ failure. And yet, several problems might arise using this approach. First, almost all ICU patients fulfill these criteria, indicating that the criteria have no discriminatory power in ICU settings. Second, an absolute SOFA score disregards the etiology of organ failure. Organ failure might have been present already before infection (e.g., due to non-infectious diseases or pre-existent comorbidities) and is therefore not caused by the infection itself. To illustrate, in the current study, up to 33% of the patients who developed sepsis-3 actually did not have an infection in a post hoc adjudication. It therefore remains essential to differentiate between infectious and non-infectious causes for organ failure. We find that future efforts should also be directed to improve (risk) stratification of septic patients and enrich classification by inclusion of additional variables, such as type of organ failure, number of different organ dysfunctions, site of infection, and possibly biomarkers [26].

Our study has some limitations. First, organ failure data were often missing before ICU admission, which was also noticed in the original assessment of sepsis-3 [13]. Second, we based our severe sepsis and septic shock definitions on consensus literature. Nevertheless, the exact application of the definitions in our study might be different from others. Of note, some of the described restraints of the sepsis-3 criteria also apply to previous sepsis definitions.

Conclusions

Virtually all patients who have suspected infection upon presentation to the ICU meet sepsis-3 criteria, making this definition less suitable for risk stratification in this setting. Furthermore, caution should be taken when using the sepsis-3 definitions to report incidences and related outcomes of sepsis, as they are very sensitive to minor variations in timing and interpretation of organ failure criteria. These criteria should therefore be specified in great detail, and applied very consistently, in all future publications on the topic.

Additional file

Additional file 1: Table S1. Missing data. Table S2. Incidence, organ failure, and mortality of sepsis-3 and MARS-sepsis. Table S3. Incidence, organ failure, and mortality of septic shock-3 and MARS-shock. (PDF 40 kb)

Abbreviations

APACHE: Acute Physiology and Chronic Health Evaluation; CI: Confidence interval; ICU: Intensive care unit; IQR: Interquartile range; MARS: Molecular Diagnosis and Risk Stratification of Sepsis; SIRS: Systemic Inflammatory Response Syndrome; SOFA: Sequential Organ Failure Assessment

Acknowledgements

We thank the MARS consortium, including the participating ICUs and research physicians of the two medical centers for their help in data acquisition.

Authors' contributions

DMV contributed to the study design, data collection, data analysis and interpretation, literature search, and writing. JF contributed to the data collection, data analysis, and interpretation. DSO helped collect the data and wrote the manuscript. JH and TP contributed to the critical revision. MJMB and OLC contributed to the study design, critical revision, and writing. PKK contributed to the study design, data collection, data analysis and interpretation, literature search, and writing. All authors read and approved the final manuscript.

Funding

This work was supported by the Center for Translational Molecular Medicine (CTMM) [grant number 04I-201].

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available. An extract can be available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The institutional review board approved an opt-out consent procedure (protocol number 10-056C).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands. ²Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands. ³Department of Medical Microbiology and Infection Control, Franciscus Gasthuis and Vlietland, Rotterdam, the Netherlands. ⁴Department of Intensive Care Medicine, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ⁵Center for Experimental and Molecular Medicine, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ⁶Division of Infectious Diseases, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ⁷Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands. ⁸Department of Medical Microbiology and Immunology, Rijnstate Hospital, Arnhem, the Netherlands.

Received: 5 June 2019 Accepted: 15 August 2019 Published online: 29 August 2019

References

- Rhee C, Kadri SS, Danner RL, Suffredini AF, Massaro AF, Kitch BT, Lee G, Klompas M. Diagnosing sepsis is subjective and highly variable: a survey of intensivists using case vignettes. Crit Care. 2016;20(1):89.
- Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. Intensive Care Med. 2012;38(5): 811–9.
- Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372(17):1629–38.
- Besen BA, Romano TG, Nassar AP Jr, Taniguchi LU, Azevedo LC, Mendes PV, Zampieri FG, Park M. Sepsis-3 definitions predict ICU mortality in a lowmiddle-income country. Ann Intensive Care. 2016;6(1):107.
- Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsi C, Sinapidis D, Koupetori M, Bristianou M, Adamis G, Mandragos K, et al. Validation of the new sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2016;23(2):104–9.
- Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, Pilcher DV, Australian, New Zealand Intensive Care Society Centre for O, Resource E. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317(3):290–300.
- Cheng B, Li Z, Wang J, Xie G, Liu X, Xu Z, Chu L, Zhao J, Yao Y, Fang X. Comparison of the performance between sepsis-1 and sepsis-3 in ICUs in China: a retrospective multicenter study. Shock. 2017;48(3):301–6.
- Fang X, Wang Z, Yang J, Cai H, Yao Z, Li K, Fang Q. Clinical Evaluation of Sepsis-1 and Sepsis-3 in the ICU. Chest. 2017;153(5):1169–76.
- Khwannimit B, Bhurayanontachai R, Vattanavanit V. Comparison of the performance of SOFA, qSOFA and SIRS for predicting mortality and organ failure among sepsis patients admitted to the intensive care unit in a middle-income country. J Crit Care. 2018;44:156–60.
- Estenssoro E, Kanoore Edul VS, Loudet CI, Osatnik J, Rios FG, Vazquez DN, Pozo MO, Lattanzio B, Palizas F, Klein F, et al. Predictive validity of sepsis-3 definitions and sepsis outcomes in critically III patients: a cohort study in 49 ICUs in Argentina. Crit Care Med. 2018;46(8):1276–83.
- Shankar-Hari M, Harrison DA, Rubenfeld GD, Rowan K. Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. Br J Anaesth. 2017;119(4):626–36.
- Donnelly JP, Safford MM, Shapiro NI, Baddley JW, Wang HE. Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classification: a retrospective population-based cohort study. Lancet Infect Dis. 2017;17(6):661–70.
- Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762–74.
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.
- Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M. Developing a new definition and assessing new clinical criteria for septic shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):775–87.
- 16. Whittaker SA, Mikkelsen ME, Gaieski DF, Koshy S, Kean C, Fuchs BD. Severe sepsis cohorts derived from claims-based strategies appear to be biased

toward a more severely ill patient population. Crit Care Med. 2013;41(4): 945–53.

- Rhee C, Jentzsch MS, Kadri SS, Seymour CW, Angus DC, Murphy DJ, Martin GS, Dantes RB, Epstein L, Fiore AE, et al. Variation in identifying sepsis and organ dysfunction using administrative versus electronic clinical data and impact on hospital outcome comparisons. Crit Care Med. 2019;47(4):493–500.
- Klein Klouwenberg PM, Ong DS, Bos LD, de Beer FM, van Hooijdonk RT, Huson MA, Straat M, van Vught LA, Wieske L, Horn J, et al. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit Care Med. 2013;41(10):2373–8.
- Klein Klouwenberg PM, Cremer OL, van Vught LA, Ong DS, Frencken JF, Schultz MJ, Bonten MJ, van der Poll T. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care. 2015;19:319.
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.
- Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003; 29(4):530–8.
- 22. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet. 2005; 365(9453):63–78.
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.
- Calandra T, Cohen J. International sepsis forum definition of infection in the ICU consensus conference: the international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538–48.
- Peelen LM, Peek N, Zwinderman KH. Statistical methods to compare different definitions of disease with an application to severe sepsis. In: Workshop on intelligent data analysis in medicine and pharmacology and knowledge-based information management in anaesthesia and intensive care: University of Amsterdam; 2003. p. 13–6. http://www.biolab.si/idamap/ idamap2003/Peelen.pdf.
- Shankar-Hari M, Harrison DA, Rowan KM. Differences in impact of definitional elements on mortality precludes International Comparisons of Sepsis Epidemiology—a cohort study illustrating the need for standardized reporting. Crit Care Med. 2016;44(12):2223–30.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

